Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Pastor

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Pharmaceuticals (Basel, Switzerland)|October 27, 2016
Aptamers: A New Technological Platform in Cancer ImmunotherapyFernando Pastor
Cancer Cell & Microenvironment|October 10, 2017
Tumor-targeted costimulation by using bi-specific aptamersFernando Pastor
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2018
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma ImmunotherapyMario M Soldevilla, Fernando Pastor
Molecular Therapy. Nucleic Acids|March 17, 2025
Lockpicking FGFR1 with aptamer-based technologyFrancesca Nonatelli, Fernando Pastor, Fernando Calvo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Use of oligonucleotide aptamer ligands to modulate the function of immune receptorsEli Gilboa, James McNamara, Fernando Pastor
Cancers|November 11, 2022
Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple MyelomaAne Amundarain, Fernando Pastor, Felipe Prósper, et al.
Nature|May 14, 2010
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayFernando Pastor, Despina Kolonias, Paloma H Giangrande, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2011
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamersFernando Pastor, Despina Kolonias, James O McNamara, et al.
Biomedicines|August 26, 2022
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune SystemDaniel Meraviglia-Crivelli, Angelina Zheleva, Martin Barainka, et al.
Biomedicines|April 3, 2021
Oligonucleotide-Based Therapies for Renal DiseasesFernando Cartón-García, Cassondra Jeanette Saande, Daniel Meraviglia-Crivelli, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Pharmaceuticals (Basel, Switzerland)|October 27, 2016
Aptamers: A New Technological Platform in Cancer ImmunotherapyFernando Pastor
Cancer Cell & Microenvironment|October 10, 2017
Tumor-targeted costimulation by using bi-specific aptamersFernando Pastor
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2018
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma ImmunotherapyMario M Soldevilla, Fernando Pastor
Molecular Therapy. Nucleic Acids|March 17, 2025
Lockpicking FGFR1 with aptamer-based technologyFrancesca Nonatelli, Fernando Pastor, Fernando Calvo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2013
Use of oligonucleotide aptamer ligands to modulate the function of immune receptorsEli Gilboa, James McNamara, Fernando Pastor
Cancers|November 11, 2022
Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple MyelomaAne Amundarain, Fernando Pastor, Felipe Prósper, et al.
Nature|May 14, 2010
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decayFernando Pastor, Despina Kolonias, Paloma H Giangrande, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2011
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamersFernando Pastor, Despina Kolonias, James O McNamara, et al.
Biomedicines|August 26, 2022
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune SystemDaniel Meraviglia-Crivelli, Angelina Zheleva, Martin Barainka, et al.
Biomedicines|April 3, 2021
Oligonucleotide-Based Therapies for Renal DiseasesFernando Cartón-García, Cassondra Jeanette Saande, Daniel Meraviglia-Crivelli, et al.
Pageof 6